Celgene, Pharmion merger closer to completion

By Lisa Kerner

Charlotte, N.C., Jan. 28 - Germany's Federal Cartel Office, the Bundeskartellamt, cleared Celgene Corp.'s pending acquisition of Pharmion Corp.

In addition, the Hart-Scott-Rodino waiting period has expired without the U.S. Federal Trade Commission requesting additional information, a news release stated.

It was previously reported that Celgene agreed to acquire Pharmion for $72 per share in a cash and stock transaction valued at $2.9 billion. The transaction is slated to close in April.

Pharmion is an oncology company based in Boulder, Colo.

Celgene is a Summit, N.J., biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.